Oh et al. Journal of Translational Medicine

https://doi.org/10.1186/s12967-024-05299-0

# **Open Access**

# Check for updates

# A scheme to underpin key mediator(s) in Salinosporamide(s) against pan-tumor via systems biology concept

(2024) 22:492

Ki-Kwang Oh<sup>1</sup>, Sang-Jun Yoon<sup>1</sup>, Seol Hee Song<sup>1</sup>, Jeong Ha Park<sup>1</sup>, Jeong Su Kim<sup>1</sup>, Min Ju Kim<sup>1</sup>, Dong Joon Kim<sup>1</sup> and Ki-Tae Suk<sup>1\*</sup><sup>©</sup>

## Dear editor,

During the last decade, Salinosporamide A (SSAA) isolated by Salinispora tropica, or Salinispora arenicola known as the p26 proteasome inhibitor (anticancer agent) led to a renaissance in marine natural products' niche. Despite the highly value, the establishment of its therapeutic mechanism is still in a maze due to the lack of the supply from marine organisms. We postulated that the key SSA(s), target(s), and mechanism(s) can be confirmed with the help of database-driven analysis, including computer screening tools. Hence, the aim of this study was to underpin the key Salinosporamide (SSA) in 11 SSAs with systems biology concept. A report demonstrated that SSAs exert potential capability to dampen cancer cell in structure-activity relationship studies (SARS) [1]. It is intriguing structure to develop schemes that would make these molecules attainable in the laboratory via total synthesis, which consists of gamma-lactam-beta-lactone bicyclic scaffold (Fig. 1A). The intent of this study was to pioneer the uppermost SSA(s) in terms of conceptual cancer treatment with a devised platform (Fig. 1B).

\*Correspondence:

Ki-Tae Suk

ktsuk@hallym.ac.kr

<sup>1</sup> Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon 24252, Korea

First, the 11 SSAs were gathered through PubChem, and SwissADME platform was adopted to identify druglike properties. All SSAs were accepted by the rigor criteria, suggesting that they can have potentiality to develop as therapeutic agent for human disease (Supplementary Table S1). Second, the common targets (61 targets) were selected between SuperPred (SP; 212 targets) and SwissTargetPrediction (STP; 268 targets), (Fig. 1C), (Supplementary Table S2). The number of 61 targets was considered as important protein-coding genes on SSAs against pan-tumor. Thereby, the protein-protein interaction (PPI) networks (55 nodes, and 198 edges) based on STRING database indicate that signal transducer and activator of transcription 3 (STAT3) is an uppermost target to modulate each target (Fig. 1D). Significantly, a previous study demonstrated that STAT3 inhibitors are key mediators on NOD-like receptor signaling pathway as antagonism [2]. A bubble plot to manifest the key signaling pathways was constructed by STRING, and R Package. Consequently, the 37 signaling pathways was linked to etiology of cancer (Supplementary Table S3). The NOD-like receptor signaling pathway with the lowest enrichment factor in them was identified an antagonistic mechanism on SSAs against cancer, indicating that the mechanism is a key mode in this study (Fig. 1E). In parallel, the corresponding targets on this mechanism were MAPK1, TBK1, and P2RX7. Holistically, 11 SSAs were associated directly with 32 targets, and 37 signaling pathways, which was constructed with Salinosporamides-Targets-Signaling pathways (STS) networks (81 nodes, and 482 edges) (Fig. 1F). Third, the identified



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.





Fig. 1 A The scaffold of Salinosporamides. B The stepwise of workflow for the study. C The overlapping targets (61) between SuperPred (212) and SwissTargetPrediction (268). D The protein–protein interaction (PPI) networks. E A bubble plot of 37 signaling pathways related to Salinosporamides against cancer. F The Salinosporamides-Targets-Signaling pathways (STS) networks. G The STAT3-Salinosporamide G conformer. H The MAPK1-Salinosporamide H conformer. I The TBK1-Salinosporamide J conformer. J The P2RX7-Salinosporamide H conformer. K The conformer's affinity of four targets and three Salinosporamides. (\*): The most stable conformer. L The energy gap (E<sub>GAP</sub>) of three key Salinosporamides via density functional theory (DFT). M The key summary of this study

targets with the 11 SSAs were docked to investigate the most stable conformers via Autodock tools. Above mentioned, STAT3-Salinosporamide G in PPI networks (Fig. 1G), MAPK1- Salinosporamide H (Fig. 1H), TBK1-Salinosporamide J (Fig. 1I), and P2RX7-Salinosporamide H (Fig. 1J) formed the most stable complexes in NODlike receptor signaling pathway, Collectively, their affinity (threshold < – 6.0 kcal/mol) on each conformer was represented in Fig. 1K. Lastly, the density functional theory (DFT) was performed to validate the chemical reactivity of the SSAs (Fig. 1L), suggesting that  $E_{GAP}$  (Highest Occupied Molecular Orbital; HOMO—Lowest Unoccupied Molecular Orbital; LUMO), Hardness ( $\eta$ ; LUMO—HOMO/2), Softness (S; 1/ $\eta$ ), and Electronegativity ( $\chi$ ;—(LUMO—HOMO)/2) of four SSAs are key parameters to confirm the chemical reactivity level. In the parameters, the range of S on anticancer agents was from 6.228 (eV) to 16.77785 (eV), including Vincristine, and Vinblastine [3]. The S value of key three SSAs was between 8.750 (eV) and 9.147 (eV), suggesting that



Fig. 1 continued



(G)



Fig. 1 continued





Fig. 1 continued

they have valid chemical reactivity level to be anticancer drugs (Supplementary Table S4). Lastly, we confirmed the toxicity of the three key SSAs (Salinosporamide G, Salinosporamide H, and Salinosporamide J) via ADMET 2.0 and ProTox-II, thereby, they had no distinct hurdles to become new therapeutic mediator (Supplementary Table S5).

This study unlocks the therapeutic desirability of SSAs with underlying mechanism against cancer. The STAT3-Salinosporamide G in PPI network, the



(K)



# The conformers' affinity (kcal/mol)

Fig. 1 continued



(M)



Fig. 1 continued

MAPK1-Salinosporamide H conformer, the TBK1-Salinosporamide J conformer, and the P2RX7-Salinosporamide H conformer were impactful epitome on NOD-like receptor signaling pathway in treating cancer. In conclusion, we propose that logical incorporation of the myriad biological data can contribute to decrypt the encoded anti-cancer agents, especially, illuminating marine organic molecules in limited amount is invaluable to cancer medicine. The key summary of this study was described in Fig. 1M.

#### Abbreviations

DFT	Density functional theory
HOMO	Highest occupied molecular orbital
LUMO	Lowest unoccupied molecular orbital
PPI	Protein-protein interaction
S	Softness
STS	Salinosporamides-targets-signaling pathways
SARS	Structure-activity relationship studies
SP	SuperPred
SSA	Salinosporamide
SSAA	Salinosporamide A
SSAs	Salinosporamides
STAT3	Signal transducer and activator of transcription 3
STP	SwissTargetPrediction
Х	Electronegativity

# **Supplementary Information**

The online version contains supplementary material available at https://doi. org/10.1186/s12967-024-05299-0.

Su	upplementary Material 1.
Su	upplementary Material 2.
Su	upplementary Material 3.
Su	upplementary Material 4.
Su	upplementary Material 5.

#### Acknowledgements

Open access publishing facilitated by Hallym University, the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology, Korea Institute for Advancement of Technology, and Bio Industrial Technology Development Program funded by the Ministry of Trade, Industry and Energy (MOTIE, Korea).

#### Author contributions

Methodology, Conceptualization, Data curation, Software, Writing-original draft: KKO, Methodology, Data curation, Software: SJY, Formal analysis, Validation: SHS, Methodology, Data curation: JHP, Methodology, Formal analysis: JSK, Data curation, Software: MJK, Supervision, Investigation, Project administration: DJK, Funding acquisition, Conceptualization, Writing-original draft, Writing – review editing: KTS.

#### Funding

This research was supported by Hallym University Research Fund, the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (NRF2019R111A3A01060447 and NRF-2020R1A6A1A03043026), Korea Institute for Advancement of Technology (P0020622), and Bio Industrial Technology Development Program (20018494) funded by the Ministry of Trade, Industry and Energy (MOTIE, Korea). All authors have read and approved the final manuscript.

#### Availability of data and materials

All data generated or analyzed during this study are included in this published article (and its Additional files).

#### Declarations

**Ethics approval and consent to participate** Not applicable.

#### **Consent for publication**

Not applicable.

#### **Competing interests**

The authors declare that they have no competing interests.

Received: 8 May 2024 Accepted: 11 May 2024 Published online: 24 May 2024

#### References

- Macherla VR, Mitchell SS, Rao Manam R, et al. Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor. J Med Chem. 2005. https://doi.org/10.1021/JM048 995.
- Velloso FJ, Trombetta-Lima M, Anschau V, et al. NOD-like receptors: major players (and targets) in the interface between innate immunity and cancer. Biosci Rep. 2019;39:1–21. https://doi.org/10.1042/BSR20181709.
- Oh KK, Yoon SJ, Eom JA, et al. A strategy to pioneer key agent(s) in Cephalotaxus alkaloids against pan-cancer via filtering methodology based on integrated pharmacology. J Transl Med. 2024;22:1–7. https://doi.org/10. 1186/S12967-024-05059-0/TABLES/1.

### **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.